Molecure Company Profile, Contacts & Intelligence

Molecure Overview

Molecure is a clinical stage biotechnology company, that uses its world leading medicinal chemistry capabilities to discover and develop first in class small molecule drug candidates that directly modulate underexplored protein targets and the function of RNA to treat multiple incurable diseases. Molecure has generated a diverse pipeline of seven distinct programs with the support of leading academic life science institutions globally. Molecure's lead drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of fibrotic and inflammatory diseases, including interstitial lung diseases such as sarcoidosis and idiopathic pulmonary fibrosis (IPF). The phase I study was completed in 2022 and the phase II study in sarcoidosis patients started in March 2024. OATD-02 is the first and only dual acting, highly potent arginase inhibitor in cancer development, involved in both tumor immunity and metabolism. In March 2023, Phase 1 clinical trial was initiated. Molecure’s headquarters and laboratories are located in Warsaw, Poland with an additional laboratories in Łódź. The company is listed on the Warsaw Stock Exchange (ticker: MOC).

Headquarters

Warsaw, Mazowieckie, Pl

Website

oncoarendi.com

Industry

Biotechnology Research

Founded

2012

Stock Symbol

MOC

NAICS

Research and Development in Biotechnology (except Nanobiotechnology)

Molecure Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

Molecure People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Molecure Workforce Composition

Seniority breakdown across 4 visible profiles.

Compare Similar Companies to Molecure

Explore companies in related markets and compare their industry and employee estimates.